BURLINGTON, ON, June 6, 2024 /PRNewswire/ - EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD). The results demonstrated efficacy for a subset of patients suffering from moderate to severe SAD. These results will guide further clinical research and the design of a robust Phase 3 program.